Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVO756 · 4 trials · 4 indications
Safety will be assessed by the total number of subjects with at least one TEAE
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | Orally administered EVO756, Dose 1 (Daily) |
| Dose 2 | EXPERIMENTAL | Orally administered EVO756, Dose 2 (Daily) |
| Placebo | PLACEBO_COMPARATOR | Placebo control (Daily) |
| Dose 3 | EXPERIMENTAL | Orally administered EVO756, Dose 3 |
| Placebo control | PLACEBO_COMPARATOR | Orally administered placebo control |
| EVO756 300 mg QD | EXPERIMENTAL | Oral EVO756 300 mg QD |
| EVO756 50 mg BID | EXPERIMENTAL | Oral EVO756 50 mg BID |
| Name | Type | Description |
|---|---|---|
| EVO756, Dose 1 | DRUG | Orally administered EVO756, Dose 1 (Daily) |
| EVO756, Dose 2 | DRUG | Orally administered EVO756, Dose 2 (Daily) |
| Placebo | DRUG | Placebo Control (Daily) |
| EVO756 | DRUG | Dose 1 |
| Placebo control | DRUG | Placebo control |
| Oral EVO756 300 mg QD | DRUG | Oral EVO756, 300 mg once daily |
| Oral EVO756 50 mg BID | DRUG | Oral EVO756 50 mg twice daily |
Key Inclusion Criteria: * Adults aged 18 to \<65 years * Migraine with or without aura, per ICHD-3 criteria * History of failure with prior preventive migraine treatments * Not currently using migraine preventive therapy Key Exclusion Criteria: * Difficulty distinguishing migraine from other head...
EVO756 is an investigational oral small molecule developed by Evommune, Inc. for dermatologic and neurologic conditions. It is being studied in atopic dermatitis, chronic inducible urticaria, chronic spontaneous urticaria, and migraine. It is a Phase 2 candidate and is not approved for any indication.
EVO756 is being evaluated for atopic dermatitis, chronic inducible urticaria, chronic spontaneous urticaria, and migraine. Clinical studies have enrolled adults 18 years and older across the United States, Canada, New Zealand, and Japan. It remains investigational and has not been approved for commercial use in any of these conditions.
EVO756 targets MRGPRX2, a receptor. By acting on this receptor, the drug is designed to modulate mast cell driven pathways relevant to itch and inflammatory skin conditions as well as migraine. MRGPRX2 is the molecular target identified for this oral small molecule candidate.
EVO756 is developed by Evommune, Inc., which trades under the ticker EVMN. The company is advancing the asset across dermatology indications and migraine. Evommune is the sole developer named for this program.
EVO756 is in Phase 2 development. It is investigational and has not been approved by the FDA or any other regulator. Studies completed to date include Phase 2b trials in atopic dermatitis and chronic spontaneous urticaria, plus a Phase 2 trial in chronic inducible urticaria.
EVO756 has been studied in NCT07150845 in atopic dermatitis, NCT06873516 in chronic spontaneous urticaria, and NCT06603220 in chronic inducible urticaria, all completed Phase 2 trials. The recruiting Phase 2 trial NCT07616128 is evaluating EVO756 in adults with migraine across the United States, Canada, and New Zealand.